

Catheter Lock-Solutions in Oncology and Parenteral Nutrition




	Anticoagulative Effectiveness, Patency	Thrombolytic Effectiveness	Antibacterial Effectiveness	Antifungal Effectiveness	Inhibition of Biofilm-Formation	Removal of Biofilm	Catheter Survival	Low Risk of Resistencies	Tolerability
TauroLock™	✓ ^{1,17}	○	✓ ^{78,9}	✓ ^{4,5,10}	✓	✓ ³²	✓	✓ ²	✓ ^{78,9,20,23,24,25}
NutriLock™	○ ¹	○	✓ ^{2,3}	✓ ^{4,5,10}	✓	○	✓	✓ ²	✓ ³
TauroLock™-HEP100	✓ ¹⁷	○	✓ ^{6,11,12,13}	✓ ^{4,5,6,10}	✓	✓ ³²	✓	✓ ²	✓ ^{11,12}
TauroLock™-U25.000	✓ ^{14,15}	✓ ^{14,15}	✓ ¹⁵	✓ ^{4,5,10}	✓	✓ ^{32,33}	✓	✓ ²	✓ ^{14,15}
TauroSept®	○ ¹	○	✓ ^{2,3}	✓ ^{4,5,10}	✓	○	✓	✓ ²	✓ ³
Heparin 100 U/ml	✓	○	✗ ^{18,19}	✗	✗	✗	✗	○	✓
4% Citrate	✓ ^{21,22,17}	○	○ ^{17,18,21,22}	○ ¹⁸	✗ ^{17,18,21,22}	○	○	✓	✓ ^{23,24,25}
70% Ethanol	✗ ²⁸	○	✓ ^{6,29}	✓ ^{6,30}	✓ ^{29,30}	✗	✗	○	✗ ²⁷
Sodium Chloride 0.9%	○	○	✗ ¹⁸	✗ ¹⁸	✗ ¹⁸	○	✗	○	✓
Antibiotics	○	○	✓ ⁶	○ ⁶	✓	○	✗	✗ ^{16,31}	✗ ³¹

✓ positive Impact
 ○ without Impact
 ✗ negative Impact

84200GB/09/21



TauroPharm GmbH
 August-Bebel-Str. 51
 D-97297 Waldbüttelbrunn
 Tel.: +49 (0) 931 304 299-0



References:

- 1 Reinmüller J. The influence of taurolidine on physiological and pathological blood coagulation and implications for its use. *Zentralbl Chir* 1999;124 Suppl 4: 13–8.
- 2 Torres-Viera C, Thauvin-Eliopoulos C, Wennerstein CB, Souli M, Sofia RD, Eliopoulos GM. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. *Antimicrob Agents Chemother* 2000; 44(6): 1720-4.
- 3 Wouters Y, Roosenboom B, Causevic E, Kievit W, Groenewoud H, Wanten G. Clinical Outcomes of Home Parenteral Nutrition Patients Using Taurolidine as Catheter Lock: A Long-Term Cohort Study. *Clin Nutr.* 2019 Oct;38(5):2210-2218.
- 4 Gorman, SP, McCafferty DF, et al. (1987). Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. *J Appl Bacteriol* 62(4): 315–20.
- 5 Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA. Antimicrobial Activity of a Novel Catheter Lock Solution. *Antimicrob Agents Chemother* 2002;46(6):1674-1679.
- 6 Visek, J.; Ryskova, L.; Safranek, R.; Lasticova, M.; Blaha, V. In vitro comparison of efficacy of catheter locks in the treatment of catheter related blood stream infection. *Clin. Nutr. ESPEN* 2019, 30, 107– 112.
- 7 Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. *Nephrol Dial Transplant.* 2004 Jun;19(6):1546-51.
- 8 Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. *J Hosp Infect.* 2012 Apr;80(4):304-9.
- 9 Łyszowska M, Kowalewski G, Szymczak M, Polnik D, Mikołajczyk A, Kaliciński P. Effects of Prophylactic Use of Taurolidine-Citrate Lock on the Number of Catheter-Related Infections in Children Under 2 Years of Age Undergoing Surgery. *J Hosp Infect.* 2019 Oct;103(2):223-226.
- 10 Olthof E.D, Rentenaar R.J, Rijs A.J.M.M, Wanten G.J.A. Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine locks. *Clin Nutr.* 2013; 32: 538-542.
- 11 Handrup MM, Møller JK, Schrøder H. Central Venous Catheters and Catheter Locks in Children with Cancer: a Prospective Randomized Trial of Taurolidine versus Heparin. *Pediatr Blood Cancer* 2013;60(8):1292-1298.
- 12 Tribler S, Brandt CF, Petersen AH, Petersen JH, Fuglsang KA, Staun M, Broebech P, Moser CE, Jeppesen PB. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial. *Am J Clin Nutr* 2017;106(3):839-848.
- 13 Merras-Salmio L, Mutanen A, Ylinen E, Rintala R, Koivusalo A, Pakarinen MP. Pediatric Intestinal Failure: The Key Outcomes for the First 100 Patients Treated in a National Tertiary Referral Center During 1984–2017. *JPEN J Parenter Enteral Nutr.* 2018;42(8):1304-13.
- 14 Al-Ali F, Hamdy AF, Hamad A, Elsayed M, Iqbal Z, Elsayed A, Ibrahim R, Tolba H, Buanan H, Fawzy A. Safety and Efficacy of Taurolidine/Urokinase Versus Taurolidine/Heparin as a Tunneled Catheter Lock Solution in Hemodialysis Patients: A Prospective, Randomized, Controlled Study *Nephrol Dial Transplant.* 2018 Apr 1;33(4):619-626.
- 15 Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bieleš B, Schairer B, Reiter T, Eskandary F, Sunder-Plassmann G, Sengoelge G. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. *Kidney Int.* 2018 Mar;93(3):753-760
- 16 Bueloni TNV, Marchi D, Caetano C, de Souza Cavalcante R, Amaral MLA, Ponce D. Cefazolin–gentamicin versus taurolidine–citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial. *International Journal of Infectious Diseases* 85 (2019) 16–21.
- 17 Zhao Y, Li Z, Zhang L, Yang J, Yang Y, Tang Y, Fu P. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. *Am J Kidney Dis.* 2014 Mar;63(3):479-90.
- 18 Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior Antimicrobial Activity of Trisodium Citrate Over Heparin for Catheter Locking. *Nephrol Dial Transplant.* 2002 Dec;17(12):2189-95.
- 19 Shanks RMQ, Donegan NP, Graber ML, Buckingham SE, Zegans ME, Cheung AL, O'Toole GA. Heparin Stimulates Staphylococcus Aureus Biofilm Formation. *Infect Immun.* 2005 Aug;73(8):4596-606.
- 20 Shewdin S, Bong YC, Okano S, Chatfield MD, Walsham J. A prospective observational study of the change in systemic ionised calcium following 4% citrate locking of venous haemodialysis catheters in intensive care patients. *Anaesth Intensive Care* 2018 | 46:4.
- 21 Macrae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). *Clin J Am Soc Nephrol.* 2008 Mar;3(2):369-74.
- 22 Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium Citrate 4% Locking Solution for Central Venous Dialysis Catheters--An Effective, More Cost-Efficient Alternative to Heparin. *Nephrol Dial Transplant.* 2007 Feb;22(2):471-6.
- 23 Schilcher G, Scharnagl H, Horina JH, Ribitsch W, Rosenkranz AR, Stojakovic T, Polaschegg H-D. Trisodium Citrate Induced Protein Precipitation in Haemodialysis Catheters Might Cause Pulmonary Embolism. *Nephrol Dial Transplant.* 2012 Jul;27(7):2953-7.
- 24 Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). *NDT Plus.* 2010 Jun;3(3):234-246.
- 25 FDA Talk Paper (Apr) 16:4-14-2000.
- 26 Goossens GA. Flushing and Locking of Venous Catheters: Available Evidence and Evidence Deficit. *Nurs Res Pract.* 2015;2015:985686.
- 27 Mermel LA and Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. *J Antimicrob Chemother.* 2014 Oct;69(10):2611-9. doi: 10.1093/jac/dku182.
- 28 Schilcher G, Schlagenhaut A, Schneditz D, Scharnagl H, Ribitsch W, Krause R, Rosenkranz AR, Stojakovic T, Horina JH. Ethanol Causes Protein Precipitation--New Safety Issues for Catheter Locking Techniques. *PLoS One.* 2013 Dec 31;8(12):e84869.
- 29 Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol Locks to Prevent Catheter-Related Bloodstream Infections in Parenteral Nutrition: A Meta-Analysis. *2012 Pediatrics,* 129 (2) 318-32.
- 30 Gerald McDonnell1,* and A. Denver Russell. Antiseptics and Disinfectants: Activity, Action, and Resistance. *Clin Microbiol Rev.* 1999 Jan; 12(1): 147–179.
- 31 Landry DL, Braden GL, Gobeille SL, Haessler SL, Vaidya CK, Sweet SJ. Emergence of Gentamicin-Resistant Bacteremia in Hemodialysis Patients Receiving Gentamicin Lock Catheter Prophylaxis. *2010 Clin J Am Soc Nephrol.* Oct;5(10):1799-804.
- 32 Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP, O'Neill E. In Vitro Approach for Identification of the Most Effective Agents for Antimicrobial Lock Therapy in the Treatment of Intravascular Catheter-Related Infections Caused by Staphylococcus aureus. *Antimicrob Agents Chemother* 2016;60(5):2923-2931.
- 33 Jiménez Hernández M, Soriano A, Filella X, Calvo M, Coll E, Rebled JM, Poch E, Graterol F, Compte MT, Maduell F, Fontserè N. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. *J Vasc Access.* 2020 Jul 21; doi: 10.1177/1129729820942040.